GE HealthCare at SBI 2025: Advancing Breast Cancer Imaging
GE HealthCare, a global frontrunner in breast health technology, is set to showcase its latest suite of advancements in diagnostic accuracy and patient-centric breast care at the 2025 Society of Breast Imaging (SBI) Symposium in Colorado Springs, Colorado, from April 24th to 27th. This year’s presentation will highlight groundbreaking innovations meticulously designed to enhance breast cancer detection, optimize clinical workflows, and elevate the overall patient experience.
A central focus of GE HealthCare’s showcase will be its next-generation mammography technologies, engineered to streamline examination workflows while prioritizing patient comfort and care. The spotlight will shine on the Pristina Via™ mammography system, a revolutionary platform that delivers effortless image acquisition, exceptional operational efficiency, and unwavering clinical confidence. This innovative system, an integral part of the acclaimed Senographe Pristina™ platform, equips mammography technologists with a sophisticated array of tools that seamlessly balance the critical demands of diagnostic precision with the need for fast-paced workflows, ultimately fostering more patient-centered breast care.
Pristina Via has been thoughtfully developed with the technologist in mind, taking in-room workflow and patient comfort to unprecedented levels. Its features include a game-changing zero-click acquisition functionality when operating within established protocols, eliminating wait times between exposures, and boasting Digital Breast Tomosynthesis (DBT) image-to-image cycle times that are up to twice as fast as comparable mammography systems currently available. Furthermore, Pristina Via offers vendor-neutral prior image comparison, significantly reducing the time spent analyzing previous examinations and enabling radiologists to reach final assessments more efficiently. Notably, the Pristina 3D STD mode achieves the lowest radiation dose across all breast thicknesses among major systems in the market.
Continuing its commitment to innovation through strategic collaborations, GE HealthCare will also highlight its expanded partnership with DeepHealth Inc., a recognized leader in AI-powered health informatics and a wholly-owned subsidiary of RadNet, Inc. The latest outcome of this collaboration is the U.S. commercial availability of SmartMammo™, an AI-powered Software as a Service (SaaS) solution that has received 510(k) clearance for use with the Pristina platform in U.S. markets. GE HealthCare will distribute SmartMammo alongside the Pristina platform, seamlessly integrating advanced artificial intelligence directly into its comprehensive breast imaging portfolio.
Artificial intelligence continues to demonstrate immense potential in revolutionizing breast cancer screening, offering benefits ranging from earlier detection and more accurate risk prediction to a reduction in unnecessary patient callbacks and more efficient workflows for breast imaging providers. SmartMammo is designed to integrate effortlessly into existing breast cancer diagnostic workflows, enhancing both diagnostic accuracy and workflow efficiencies.
The platform facilitates rapid image loading and real-time data rendering of multimodality images, accessible from any workstation and location, and can be seamlessly integrated into a customer’s existing IT infrastructure. DeepHealth’s AI-powered breast cancer detection capabilities offer automatic lesion localization and a sophisticated degree of suspicion assessment, proving effective across diverse patient populations and in dense breast tissue. The combination of GE HealthCare’s Pristina Via and SmartMammo provides a powerful synergy, offering enhanced workflow efficiency for both technologists and radiologists, coupled with advanced image interpretation features, including automatic lesion localization.
“We are deeply committed to delivering innovative technologies and comprehensive end-to-end solutions that address the most significant challenges our customers face in breast cancer detection,” states Pooja Pathak, Vice President and General Manager of Mammography at GE HealthCare. “Our ultimate goal is to empower clinicians with the tools they need to provide efficient, accurate, and personalized diagnoses to their patients. With Pristina Via and SmartMammo, we have significantly streamlined both the examination and radiology workflows in breast cancer screening and diagnostics, allowing clinicians to prioritize what matters most – exceptional patient care.”
Further underscoring its commitment to advancing breast cancer detection, GE HealthCare will also showcase the Invenia™ Automated Breast Ultrasound (ABUS) Premium. This groundbreaking technology is the first FDA-approved breast ultrasound system indicated as an adjunct to mammography and specifically designed to improve cancer detection in women with dense breast tissue. Studies conducted across the U.S. and Europe indicate that a significant portion of the female population – 40% overall and 70% of Asian women – have dense breast tissue, which can obscure tumors on traditional mammograms.
For these patients, the addition of ABUS screening, when used in conjunction with mammography, has demonstrated a remarkable 35.7% increase in cancer detection rates compared to mammography alone. The latest Invenia ABUS Premium is engineered to deliver optimal clinical outcomes through its innovative, patient-friendly, and efficient AI-driven technology. It features new integrated Verisound™ AI and AI Assistant, ensuring faster and more reproducible scanning and reading processes with exceptional image quality. This translates to increased clinical confidence, enhanced workflow productivity, and improved detection of breast cancer in women with dense breasts.
The SenoBright™ HD Contrast Enhanced Mammography (CEM) is another key advancement to be highlighted. This next-level mammogram helps to overcome the masking effect of fibroglandular breast tissue and amplifies the tumor signal, leading to increased diagnostic confidence. SenoBright HD enables imaging exams to be completed in under seven minutes and facilitates the detection of lesions that might otherwise go unnoticed, providing patients with prompt answers and alleviating the anxiety associated with inconclusive examinations.
Complementing its diagnostic offerings, GE HealthCare will also feature Serena Bright™, a contrast-guided biopsy system. This innovative system empowers providers to visualize lesions using CEM and perform biopsies with greater certainty. This allows patients to undergo breast biopsy procedures using the same familiar mammography equipment, within a comfortable setting and with familiar staff, helping to reduce some of the inherent stress associated with a biopsy.
Attendees of the SBI 2025 Symposium are encouraged to visit GE HealthCare’s booth #407 to learn more about these personalized breast cancer screening solutions and their potential to transform patient care.
About GE HealthCare Technologies Inc.
GE HealthCare is a trusted partner and leading global healthcare solutions provider, at the forefront of innovating medical technology, pharmaceutical diagnostics, and integrated, cloud-first AI-enabled solutions, services, and data analytics. With a mission to make hospitals and health systems more efficient, clinicians more effective, therapies more precise, and patients healthier and happier, GE HealthCare has been serving patients and providers for over 125 years.
The company is committed to advancing personalized, connected, and compassionate care while simplifying the patient’s journey across care pathways. Its Imaging, Advanced Visualization Solutions, Patient Care Solutions, and Pharmaceutical Diagnostics businesses work collaboratively to improve patient care from screening and diagnosis to therapy and monitoring. With a global team of approximately 53,000 colleagues and a $19.7 billion business, GE HealthCare is dedicated to creating a world where healthcare has no limits and is proud to be recognized as one of the 2025 Fortune World’s Most Admired Companies™.
